By Raji Unnikrishnan
A MAJOR drug being used in Bahrain to treat Covid-19 is effective against all mutations of the Omicron variant, according to a new study.
Sotrovimab – developed by UK’s GlaxoSmithKline (GSK) and US firm Vir Biotechnology – also reduces the chances of hospitalisation and death in patients with mild to moderate Covid-19 symptoms by 79 per cent, the in-house trial by GSK revealed.
No serious adverse reactions were reported in the 24,000 people involved in the trial, the companies said.
Click here to read more.
